Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | MDS novel agents & HMAs

David Steensma • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine Decitabine

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the future of hypomethylating agents (HMA) and oral agents as treatment options for myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from David Steensma

2:51
MDS and Agent Orange
David Steensma • 5 Mar 2020
0:52
Azacitidine in the treatment of MDS
David Steensma • 5 Mar 2020
1:16
State of the art: MDS
David Steensma • 5 Mar 2020
1:32
Clonal hematopoiesis & MDS
David Steensma • 5 Mar 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals